Valuation: Seres Therapeutics, Inc.

Market Cap 44.54M 38.6M 36.19M 33M 62.09M 4.25B 63.08M 426M 166M 2.13B 167M 164M 7.1B P/E 2026 *
-1.27x
P/E 2027 * -0.91x
Enterprise Value 44.54M 38.6M 36.19M 33M 62.09M 4.25B 63.08M 426M 166M 2.13B 167M 164M 7.1B EV / Sales 2026 *
3.23x
EV / Sales 2027 * 163x
Free-Float
88.52%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day-5.08%
1 week-7.05%
Current month-7.25%
1 month-20.28%
3 months-42.27%
6 months-47.11%
Current year-69.89%
1 week 4.46
Extreme 4.46
5.05
1 month 4.46
Extreme 4.46
5.69
Current year 4.46
Extreme 4.46
16.42
1 year 4.46
Extreme 4.46
29.98
3 years 4.46
Extreme 4.46
77
5 years 4.46
Extreme 4.46
233.8
10 years 4.46
Extreme 4.46
770
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2026
Chief Executive Officer 58 31/07/2025
President 51 01/03/2026
Director TitleAgeSince
Chairman 70 01/03/2026
Director/Board Member 50 14/01/2019
Director/Board Member 80 31/03/2015
Date Insider Type Main position Quantity % Market Cap.
08/07/26 Free

General Counsel

7,500 0.0774%
08/07/26 Free

Director

6,500 0.0671%
08/07/26 Free

Director

6,500 0.0671%
Change 5-day change 1-year change 3-year change Capi.($)
-5.08%-7.05%-71.95%-94.21% 44.54M
+2.07%+13.76%+65.44%+106.53% 71.56B
-1.30%-2.38%+33.78%+62.90% 54.43B
-4.50%-4.69%+2.82%+463.22% 27.59B
-1.27%-1.57%+46.46%+6.09% 23.91B
-0.67%+1.02%-18.32%-13.84% 23.14B
0.00%+1.45%+39.05%-20.00% 18.65B
+0.35%+12.02%+257.19%+466.50% 18.64B
-0.95%-3.52%+20.04%+613.01% 16.01B
+0.46%-3.05%+31.49%+135.18% 12.54B
Average -1.09%+2.95%+40.60%+172.54% 26.65B
Weighted average by Cap. -0.36%+3.63%+50.74%+163.14%

Financials

2026 *2027 *
Net sales 13.8M 11.96M 11.21M 10.22M 19.23M 1.32B 19.54M 132M 51.53M 659M 51.8M 50.68M 2.2B 274K 237K 222K 203K 381K 26.1M 387K 2.62M 1.02M 13.07M 1.03M 1M 43.59M
Net income -37.49M -32.49M -30.46M -27.77M -52.26M -3.58B -53.1M -359M -140M -1.79B -141M -138M -5.97B -78.95M -68.44M -64.16M -58.5M -110M -7.54B -112M -755M -295M -3.77B -296M -290M -12.58B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
13/08/26 US$4.480 -5.08% 81,900
12/08/26 US$4.720 +1.72% 45,371
11/08/26 US$4.640 -7.20% 84,677
10/08/26 US$5.000 +2.67% 84,595
07/08/26 US$4.870 +1.04% 62,321
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.480USD
Average target price
17.00USD
Spread / Average Target
+279.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock